Wilson Disease
Conditions
Interventions
Observation group:Wilson disease patient
Control Group:Healthy volunteer
Sponsors
The First Affiliated Hospital of Anhui University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Observation group: 1) Meets the diagnostic criteria for Wilson disease; 2) Age 18-45 years, both sexes; 3) Patients or their families have signed the informed consent form. Control group: 1) Healthy volunteers from the same period; 2) Age 18-45 years, both sexes; 3) Voluntarily participate in this study and have signed the informed consent form.
Exclusion criteria
Exclusion criteria: Observation Group: 1) Coexisting active diseases that may significantly impair cardiovascular system function (e.g., severe liver/renal dysfunction, uncontrolled severe infection, thyroid crisis, etc.); 2) Presence of contraindications or high-risk factors for cardiac magnetic resonance (CMR); 3) Poor quality of CMR images; 4) Allergy to the investigational drug; 5) Unable to cooperate to complete the entire trial process. Control Group: 1) Presence of any cardiovascular disease (including hypertension, coronary artery disease, cardiomyopathy, heart failure, arrhythmia, etc.) or other systemic diseases that may affect myocardial structure and function (e.g., Wilson disease, chronic liver disease, chronic kidney disease, diabetes, thyroid dysfunction, etc.); 2) Presence of contraindications or high-risk factors for CMR; 3) Poor quality of CMR images; 4) Allergy to the investigational drug; 5) Unable to cooperate to complete the entire trial process; 6) Pregnant or breastfeeding women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| End-systolic volume;End-diastolic volume;Stroke volume;Cardiac output;Ejection Fraction;Left ventricular end-systolic volume index;Left ventricular end-diastolic volume index;Content T1 value;Content T2 Value;Extracellular Volume Fraction; | — |
Secondary
| Measure | Time frame |
|---|---|
| High-Sensitivity Troponin I;N-terminal pro-B-type natriuretic peptide;Echocardiogram;12-lead standard electrocardiogram; | — |
Countries
China
Contacts
Public ContactWang Han
The First Affiliated Hospital of Anhui University of Chinese Medicine
Outcome results
None listed